Q-omics provides the consensus-scored PDXDC1 profile across patient tissues and cancer cell-line models. PDXDC1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PDXDC1 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, PDXDC1 protein abundance shows 23,723 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LUAD, and GBM as cancer lineages where PDXDC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDXDC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDXDC1 survival associations across molecular data types. PDXDC1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDXDC1 RNA expression–survival associations across cancer types. High PDXDC1 expression shows unfavorable associations in UVM, MESO, LUAD and HNSC, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PDXDC1 RNA expression.
This table summarizes PDXDC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PDXDC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDXDC1 shows higher tumor expression in LUAD, BRCA, UCEC, BLCA, STAD and PAAD. The LUAD box plot shows higher PDXDC1 RNA expression in tumor versus normal tissue (log2 FC = +0.836, t-test p < 0.001).
This table shows molecular features associated with PDXDC1 in patient tissues and cancer cell lines. In patient samples, PDXDC1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDXDC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
